 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
21 March 2000 | Volume 132 Issue 6 | Pages 425-434
Background: Pulmonary hypertension is a progressive and often fatal complication of the scleroderma spectrum of disease for which no treatment has been proven effective in a randomized trial.
Objective: To determine the effect of epoprostenol on pulmonary hypertension secondary to the scleroderma spectrum of disease.
Design: Randomized, open-label, controlled trial.
Setting: 17 pulmonary hypertension referral centers.
Patients: 111 patients with moderate to severe pulmonary hypertension.
Intervention: Epoprostenol plus conventional therapy or conventional therapy alone.
Measurements: The primary outcome measure was exercise capacity. Other measures were cardiopulmonary hemodynamics, signs and symptoms of pulmonary hypertension and scleroderma, and survival.
Results: Exercise capacity improved with epoprostenol (median distance walked in 6 minutes, 316 m at 12 weeks compared with 270 m at baseline) but decreased with conventional therapy (192 m at 12 weeks compared with 240 m at baseline). The difference between treatment groups in the median distance walked at week 12 was 108 m (95% CI, 55.2 m to 180.0 m) (P < 0.001). Hemodynamics improved at 12 weeks with epoprostenol. The changes in mean pulmonary artery pressure for the epoprostenol and conventional therapy groups were–5.0 and 0.9 mm Hg, respectively (difference, –6.0 mm Hg [CI, –9.0 to –3.0 mm Hg], and the mean changes in pulmonary vascular resistance were –4.6 and 0.9 mm Hg/L per minute, respectively (difference, –5.5 mm Hg/L per minute [CI, –7.3 to –3.7 mm Hg/L per minute]. Twenty-one patients treated with epoprostenol and no patients receiving conventional therapy showed improved New York Heart Association functional class. Borg Dyspnea Scores and Dyspnea-Fatigue Ratings improved in the epoprostenol group. Trends toward greater improvement in severity of the Raynaud phenomenon and fewer new digital ulcers were seen in the epoprostenol group. Four patients in the epoprostenol group and five in the conventional therapy group died (P value not significant). Side effects of epoprostenol therapy included jaw pain, nausea, and anorexia. Adverse events related to the epoprostenol delivery system included sepsis, cellulitis, hemorrhage, and pneumothorax (4% incidence for each condition).
Conclusions: Continuous epoprostenol therapy improves exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary hypertension due to the scleroderma spectrum of disease.
Author and Article Information
From University of Colorado, Denver, Colorado; Duke University, Durham, North Carolina; Mayo Clinic, Rochester, Minnesota; University of California, Los Angeles, Los Angeles, California; University of Maryland and Johns Hopkins University, Baltimore, Maryland; Rush-Presbyterian Medical Center, Chicago, Illinois; Columbia-Presbyterian Medical Center, New York, New York; Glaxo Wellcome, Inc., Research Triangle Park, North Carolina; Vanderbilt University, Nashville, Tennessee; University of Pittsburgh, Pittsburgh, Pennsylvania; Baylor College of Medicine, Houston, Texas; Wayne State University, Detroit, Michigan; University of Alabama, Birmingham, Alabama; University of Washington, Seattle, Washington; LDS Hospital, Salt Lake City, Utah; Brown University, Providence, Rhode Island; McGill University, Montreal, Quebec, Canada; The Cleveland Clinic, Cleveland, Ohio; and Harbor-UCLA Medical Center, Torrance, California.
Presented at the 71st Scientific Sessions of the American Heart Association, 11 November 1998, Dallas, Texas, and published in abstract form (Circulation. 1998; Suppl 1:I614). The rheumatologic outcomes of the study were presented at the 62nd Annual Scientific Meeting of the American College of Rheumatology, 10 November 1998, San Diego, California, and were published in abstract form (Arthritis Rheum. 1998; 41[Suppl]:A1243).
Acknowledgments: The authors thank the members of the Data Safety Monitoring Board, study coordinators, study monitors, and pharmacists who participated in this trial.
Grant Support: By Glaxo Wellcome, Inc. Drs. Badesch, Tapson, McGoon, Brundage, and Rubin served on the Steering Committee for the Development of Epoprostenol in Secondary Pulmonary Hypertension and were paid consultants to Glaxo Wellcome, Inc. Dr. Wigley was also a paid consultant to Glaxo Wellcome, Inc.
Requests for Single Reprints: David B. Badesch, MD, University of Colorado Health Sciences Center, Division of Pulmonology, C272, 4200 East Ninth Avenue, Denver, CO 80262; e-mail, David.Badesch{at}UCHSC.edu.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Badesch: Division of Pulmonology, University of Colorado Health Sciences Center, C272, 4200 East Ninth Avenue, Denver, CO 80262.
Dr. Tapson: Division of Pulmonary Medicine, Duke University Medical Center, DUMN Box 31175, Durham, NC 27710.
Dr. McGoon: Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
Dr. Brundage: Bend Memorial Clinic, 1501 NE Medical Center Drive, Bend, OR 97701.
Dr. Rubin: University of California, San Diego, School of Medicine, 200 West Arbor Drive, Westwing Room 135, San Diego, CA 92103.
Dr. Wigley: Division of Rheumatology, Johns Hopkins University, 720 Rutland Avenue, Room 1059 South, Baltimore, MD 21205.
Dr. Rich: Section of Cardiology, Rush-Presbyterian-St. Luke's Medical Center, 1725 West Harrison Street, Suite 945, Chicago, IL 60612.
Dr. Barst: Babies Hospital, Columbia-Presbyterian Medical Center, Pediatric-Cardiology Center BH-2 North, Room 262, 3959 Broadway, New York, NY 10032.
Dr. Barrett, Mr. Kral, Ms. Jöbsis, Mr. Decker, and Dr. Knobil: Glaxo Wellcome, Inc., 5 Moore Drive, Research Triangle Park, NC 27709.
Drs. Loyd and Robbins: Pulmonary Medicine, Vanderbilt University Medical Center, 1161 21st Avenue South, Room T-1217 MCN, Nashville, TN 37232-2650.
Dr. Murali: Transplantation Cardiology, University of Pittsburgh Medical Center, 556 Scaife Hall, 200 Lothrop Street, Pittsburgh, PA 15213.
Dr. Frost: Pulmonary Section, Lung Transplant Program, Baylor College of Medicine, 6550 Fannin Smith Tower, Suite 1236, Houston, TX 77030.
Dr. Girgis: Division of Pulmonary and Critical Care Medicine, Wayne State University School of Medicine, Harper Hospital, 3-Hudson, 3990 John R, Detroit, MI 48201.
Dr. Bourge: Division of Cardiovascular Diseases, University of Alabama, 1900 University Boulevard, 321-M Tinsley Harrison Tower, Birmingham, AL 35294.
Dr. Ralph: Pulmonary and Critical Care Medicine, University of Washington Medical Center, Box 356522, Seattle, WA 98195-6522.
Dr. Elliott: Pulmonary Division, LDS Hospital, Ninth Avenue and C Street, Salt Lake City, UT 84143.
Dr. Hill: Pulmonary Division, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903.
Dr. Langleben: Jewish General Hospital, Room E-258, 3755 chemin Côte Ste-Catherine, Montreal, Quebec H3T 1E2, Canada.
Dr. Schilz: Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195.
Dr. McLaughlin: Section of Cardiology, Rush Presbyterian-St. Luke's Medical Center, 1725 West Harrison Street, Suite 020, Chicago, IL 60612.
Dr. Groves: Division of Cardiology, B132, University of Colorado Health Sciences Center, 4300 East Ninth Avenue, Denver, CO 80262.
Dr. Shapiro: Division of Cardiology, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90509.
Dr. Medsger: University of Pittsburgh, 502 Kaufmann Building, 3471 Fifth Avenue, Pittsburgh, PA 15213.
Dr. Gaine: Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, 10 South Pine Street, Room 800, Baltimore, MD 21201.
Dr. Horn: Cardiology Division, Department of Medicine, Columbia-Presbyterian Medical Center, 630 West 168th Street, Box 93, New York, NY 10032.
Author Contributions: Conception and design: D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, F.M. Wigley, S. Rich, R.J. Barst, P.S. Barrett, K.M. Kral, M.M. Jöbsis, R.C. Bourge, C.G. Elliott, B.M. Groves.
Analysis and interpretation of the data: D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, F.M. Wigley, S. Rich, R.J. Barst, P.S. Barrett, K.M. Kral, M.M. Jöbsis, R.C. Bourge, D. Langleben, J.C. Decker, K. Knobil.
Drafting of the article: D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, F.M. Wigley, K.M. Kral, M.M. Jöbsis, D. Langleben, T.A. Medsger, J.C. Decker, K. Knobil.
Critical revision of the article for important intellectual content: D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, F.M. Wigley, S. Rich, R.J. Barst, P.S. Barrett, K.M. Kral, M.M. Jöbsis, J.E. Loyd, S. Murali, A.E. Frost, D. Ralph, C.G. Elliott, D. Langleben, T.A. Medsger, J.C. Decker, K. Knobil.
Final approval of the article: D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, F.M. Wigley, S. Rich, R.J. Barst, K.M. Kral, M.M. Jöbsis, J.E. Loyd, S. Murali, A.E. Frost, R.E. Girgis, R.C. Bourge, D. Ralph, C.G. Elliott, D. Langleben, J.C. Decker, K. Knobil.
Provision of study materials or patients: D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, S. Rich, F.M. Wigley, R.J. Barst, J.E. Loyd, S. Murali, A.E. Frost, R.E. Girgis, R.C. Bourge, D. Ralph, C.G. Elliott, N.S. Hill, D. Langleben, R.J. Schilz, V.V. McLaughlin, I.M. Robbins, B.M. Groves, S. Shapiro, T.A. Medsger, S.P. Gaines, E. Horn.
Statistical expertise: K.M. Kral, J.C. Decker.
Obtaining of funding: D.B. Badesch, M.M. Jöbsis.
Administrative, technical, or logistic support: M.M. Jöbsis, T.A. Medsger.
Collection and assembly of data: M.D. McGoon, K.M. Kral, M.M. Jöbsis, J.E. Loyd, R.E. Girgis, C.G. Elliott, I.M. Robbins, J.C. Decker. ARTICLE
Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease
A Randomized, Controlled Trial
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  O. Kowal-Bielecka, M. Delcroix, A. Vonk-Noordegraaf, M. M. Hoeper, and R. Naeije Outcome measures in pulmonary arterial hypertension associated with systemic sclerosis Rheumatology, October 1, 2008; 47(suppl_5): v39 - v41. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C P Denton, J E Pope, H-H Peter, A Gabrielli, A Boonstra, F H J van den Hoogen, G Riemekasten, S De Vita, A Morganti, M Dolberg, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases Ann Rheum Dis, September 1, 2008; 67(9): 1222 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Galie, H. Olschewski, R. J. Oudiz, F. Torres, A. Frost, H. A. Ghofrani, D. B. Badesch, M. D. McGoon, V. V. McLaughlin, E. B. Roecker, et al. Ambrisentan for the Treatment of Pulmonary Arterial Hypertension: Results of the Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy (ARIES) Study 1 and 2 Circulation, June 10, 2008; 117(23): 3010 - 3019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Avouac, J Wipff, A Kahan, and Y Allanore Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials Ann Rheum Dis, June 1, 2008; 67(6): 808 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Wrishko, J. Dingemanse, A. Yu, C. Darstein, D. L. Phillips, and M. I. Mitchell Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects J. Clin. Pharmacol., May 1, 2008; 48(5): 610 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Chin and L. J. Rubin Pulmonary arterial hypertension. J. Am. Coll. Cardiol., April 22, 2008; 51(16): 1527 - 1538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Gomberg-Maitland and H. Olschewski Prostacyclin therapies for the treatment of pulmonary arterial hypertension Eur. Respir. J., April 1, 2008; 31(4): 891 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Heart, March 1, 2008; 94(Suppl_1): i1 - i41. [Full Text] [PDF]
|
|
|
|
 |
|
 National Pulmonary Hypertension Centres of the UK Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41. [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Moore and E. R. H. DeSantis Treatment of complications associated with systemic sclerosis Am. J. Health Syst. Pharm., February 15, 2008; 65(4): 315 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. McSwain, R. Benza, S. Shapiro, N. Hill, R. Schilz, C. G. Elliott, D. L. Zwicke, R. J. Oudiz, J. P. Staszewski, C. P. Arneson, et al. Dose Proportionality of Treprostinil Sodium Administered by Continuous Subcutaneous and Intravenous Infusion J. Clin. Pharmacol., January 1, 2008; 48(1): 19 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Thenappan, S. J. Shah, S. Rich, and M. Gomberg-Maitland A USA-based registry for pulmonary arterial hypertension: 1982 2006 Eur. Respir. J., December 1, 2007; 30(6): 1103 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.G. Coghlan and J. Davar How should we assess right ventricular function in 2008? Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H22 - H28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E Girgis, A. E Frost, N. S Hill, E. M Horn, D. Langleben, V. V McLaughlin, R. J Oudiz, I. M Robbins, J. R Seibold, S. Shapiro, et al. Selective endothelinA receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease Ann Rheum Dis, November 1, 2007; 66(11): 1467 - 1472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rubenfire, V. V. McLaughlin, R. P. Allen, G. Elliott, M. H. Park, M. Wade, and R. Schilz Transition From IV Epoprostenol to Subcutaneous Treprostinil in Pulmonary Arterial Hypertension: A Controlled Trial Chest, September 1, 2007; 132(3): 757 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Helman Jr, A. W. Brown, J. L. Jackson, and A. F. Shorr Analyzing the Short-term Effect of Placebo Therapy in Pulmonary Arterial Hypertension: Potential Implications for the Design of Future Clinical Trials Chest, September 1, 2007; 132(3): 764 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Takaoka, J. L. Faul, and R. Doyle Current Therapies for Pulmonary Arterial Hypertension Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2007; 11(2): 137 - 148. [Abstract] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. McLaughlin Medical Therapy for Pulmonary Arterial Hypertension: Updated ACCP Evidence-Based Clinical Practice Guidelines Chest, June 1, 2007; 131(6): 1917 - 1928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E Lammers, A. A Hislop, Y. Flynn, and S. G Haworth Epoprostenol treatment in children with severe pulmonary hypertension Heart, June 1, 2007; 93(6): 739 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Widlitz, S. McDevitt, G. R. Ward, and A. Krichman Practical Aspects of Continuous Intravenous Treprostinil Therapy Crit. Care Nurse, April 1, 2007; 27(2): 41 - 50. [Full Text] [PDF]
|
|
|
|
|
|
S. C. Mathai, R. E. Girgis, M. R. Fisher, H. C. Champion, T. Housten-Harris, A. Zaiman, and P. M. Hassoun Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension Eur. Respir. J., March 1, 2007; 29(3): 469 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M H Buch, C P Denton, D E Furst, L Guillevin, L J Rubin, A U Wells, M Matucci-Cerinic, G Riemekasten, P Emery, H Chadha-Boreham, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test Ann Rheum Dis, February 1, 2007; 66(2): 169 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. O. Villalba, P. D. Sampaio-Barros, M. C. Pereira, E. M. F. P. Cerqueira, C. A. Leme Jr, J. F. Marques-Neto, and I. A. Paschoal Six-Minute Walk Test for the Evaluation of Pulmonary Disease Severity in Scleroderma Patients Chest, January 1, 2007; 131(1): 217 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Barst, N. Galie, R. Naeije, G. Simonneau, R. Jeffs, C. Arneson, and L. J. Rubin Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil Eur. Respir. J., December 1, 2006; 28(6): 1195 - 1203. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. V. McLaughlin, R. J. Oudiz, A. Frost, V. F. Tapson, S. Murali, R. N. Channick, D. B. Badesch, R. J. Barst, H. H. Hsu, and L. J. Rubin Randomized Study of Adding Inhaled Iloprost to Existing Bosentan in Pulmonary Arterial Hypertension Am. J. Respir. Crit. Care Med., December 1, 2006; 174(11): 1257 - 1263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Distler, F. Behrens, D. Huscher, I. Foeldvari, A. Zink, P. Nash, C. P. Denton, M. Humbert, M. Matucci-Cerinic, J. Seibold, et al. Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis Rheumatology, December 1, 2006; 45(12): 1455 - 1457. [Full Text] [PDF]
|
|
|
|
|
|
M. K. Steiner, I. R. Preston, J. R. Klinger, G. J. Criner, A. B. Waxman, H. W. Farber, and N. S. Hill Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest, November 1, 2006; 130(5): 1471 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D J Fox and R S Khattar Pulmonary arterial hypertension: classification, diagnosis and contemporary management Postgrad. Med. J., November 1, 2006; 82(973): 717 - 722. [Full Text] [PDF]
|
|
|
|
|
|
S. Rich The current treatment of pulmonary arterial hypertension: time to redefine success. Chest, October 1, 2006; 130(4): 1198 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Distler and A. Pignone Pulmonary arterial hypertension and rheumatic diseases--from diagnosis to treatment Rheumatology, October 1, 2006; 45(suppl_4): iv22 - iv25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Kahler and D. Colleselli Pulmonary arterial hypertension (PAH) in connective tissue diseases Rheumatology, October 1, 2006; 45(suppl_3): iii11 - iii13. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Riemekasten and C. Sunderkotter Vasoactive therapies in systemic sclerosis Rheumatology, October 1, 2006; 45(suppl_3): iii49 - iii51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. V. McLaughlin and M. D. McGoon Pulmonary Arterial Hypertension Circulation, September 26, 2006; 114(13): 1417 - 1431. [Full Text] [PDF]
|
|
|
|
|
|
O. Sanchez, O. Sitbon, X. Jais, G. Simonneau, and M. Humbert Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest, July 1, 2006; 130(1): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M H Williams, C Das, C E Handler, M R Akram, J Davar, C P Denton, C J Smith, C M Black, and J G Coghlan Systemic sclerosis associated pulmonary hypertension: improved survival in the current era Heart, July 1, 2006; 92(7): 926 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Lang, M. Gomez-Sanchez, M. Kneussl, R. Naeije, P. Escribano, N. Skoro-Sajer, and J.-L. Vachiery Efficacy of Long-term Subcutaneous Treprostinil Sodium Therapy in Pulmonary Hypertension Chest, June 1, 2006; 129(6): 1636 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J G Coghlan and C Handler Connective tissue associated pulmonary arterial hypertension Lupus, March 1, 2006; 15(3): 138 - 142. [Abstract] [PDF]
|
|
|
|
|
|
N Galie, A Manes, K V Farahani, F Pelino, M Palazzini, L Negro, S Romanazzi, and A Branzi Pulmonary arterial hypertension associated to connective tissue diseases Lupus, September 1, 2005; 14(9): 713 - 717. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Engel and S. G Rockson Treprostinil for the treatment of severe digital necrosis in systemic sclerosis Vascular Medicine, February 1, 2005; 10(1): 29 - 32. [Abstract] [PDF]
|
|
|
|
 |
|
 Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology Eur. Heart J., December 2, 2004; 25(24): 2243 - 2278. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Humbert, O. Sitbon, and G. Simonneau Treatment of Pulmonary Arterial Hypertension N. Engl. J. Med., September 30, 2004; 351(14): 1425 - 1436. [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines Chest, July 1, 2004; 126(1_suppl): 35S - 62S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Fishman Primary pulmonary arterial hypertension: A look back J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 2S - 4S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Simonneau, N. Galie, L. J. Rubin, D. Langleben, W. Seeger, G. Domenighetti, S. Gibbs, D. Lebrec, R. Speich, M. Beghetti, et al. Clinical classification of pulmonary hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 5S - 12S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Hoeper, R. J. Oudiz, A. Peacock, V. F. Tapson, S. G. Haworth, A. E. Frost, and A. Torbicki End points and clinical trial designs in pulmonary arterial hypertension: Clinical and regulatory perspectives J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 48S - 55S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst Prostanoid therapy for pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 56S - 61S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Ghofrani, J. Pepke-Zaba, J. A. Barbera, R. Channick, A. M. Keogh, M. A. Gomez-Sanchez, M. Kneussl, and F. Grimminger Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 68S - 72S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Galie, W. Seeger, R. Naeije, G. Simonneau, and L. J. Rubin Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension J. Am. Coll. Cardiol., June 16, 2004; 43(12_Suppl_S): 81S - 88S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Mukerjee, D. St. George, C. Knight, J. Davar, A. U. Wells, R. M. Du Bois, C. M. Black, and J. G. Coghlan Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis Rheumatology, April 1, 2004; 43(4): 461 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Article
